Celularity (NASDAQ:CELU) Upgraded to Buy at WBB Securities

Key Points

• Celularity has been upgraded to a "buy" rating by WBB Securities, with a price target of $6.00, indicating a potential upside of 173.97% from its previous close.
• Shares of Celularity experienced a 3.8% increase during midday trading, reaching $2.19, while the company has a market capitalization of approximately $58.45 million.
• Despite the upgrade from WBB Securities, Wall Street Zen downgraded Celularity from "hold" to "sell," reflecting mixed sentiment among analysts about the stock.

Celularity (NASDAQ:CELU - Get Free Report) was upgraded by equities research analysts at WBB Securities from a "hold" rating to a "buy" rating in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. WBB Securities' price target suggests a potential upside of 158.62% from the company's previous close.

Separately, Wall Street Zen downgraded shares of Celularity from a "hold" rating to a "sell" rating in a research report on Friday, September 5th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Celularity currently has an average rating of "Buy" and an average price target of $6.00.

Celularity Stock Performance

NASDAQ:CELU traded down $0.01 during mid-day trading on Tuesday, hitting $2.32. The stock had a trading volume of 57,227 shares, compared to its average volume of 130,336. The stock has a market capitalization of $61.92 million, a price-to-earnings ratio of -0.73 and a beta of 0.81. The company has a 50 day simple moving average of $3.02 and a 200-day simple moving average of $2.20. Celularity has a 52 week low of $1.00 and a 52 week high of $5.22. The company has a current ratio of 0.25, a quick ratio of 0.19 and a debt-to-equity ratio of 4.07.

Celularity (NASDAQ:CELU - Get Free Report) last issued its quarterly earnings data on Friday, August 29th. The company reported ($1.02) earnings per share for the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%. The firm had revenue of $5.74 million during the quarter.

Hedge Funds Weigh In On Celularity

Several hedge funds have recently made changes to their positions in CELU. Valmark Advisers Inc. acquired a new position in shares of Celularity in the 2nd quarter worth approximately $98,000. Two Sigma Investments LP acquired a new position in shares of Celularity in the 4th quarter worth approximately $93,000. Bank of America Corp DE grew its stake in shares of Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock worth $73,000 after purchasing an additional 35,023 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Celularity in the 1st quarter worth approximately $34,000. Finally, XTX Topco Ltd grew its stake in shares of Celularity by 106.4% in the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock worth $42,000 after purchasing an additional 11,057 shares during the last quarter. Institutional investors and hedge funds own 19.02% of the company's stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.